Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

An Eco-Friendly WORLD is a DREAM of all and ECO Blu Products ECOB is
one such stepping stone towards it.  www.EcoBluProducts.com

ECOB  Products; a fully integrated chemical coating plant located in
Southern California and Northeast Texas, poised to impact housing
industry on many levels.

ECOB aims at preventing rot, mildew, fungus, termite infestation,
along with effective fire retardant. Coated wood lasts Lifelong;
increases sustainability of forests.

Estimated Market demand for treated lumber is $11 Billion by 2010.
Demand for lumber and engineering wood products is expected to be $18
Billion.

The management team made up to Founder Steve Conboy and EVP Mark
Vuzzo, having more than 30 years of experience each; and the Advisory
team consisting of Ken McClelland- president of McClelland
Organization. The ECoBlu seems to be in have a great leaders.

ECO Blu is superbly positioned to take advantage in this rapidly
increasing eco friendly and Green market.

ECOB  have an estimated growth of about $6 billion within 3 years.
This would represent a gain of over 200% from current level.

The wood chemical market enjoyed $2 Billion in revenues in 2007, ones
the global financial market recovers the revenues are expected to
exceed the numbers.

Partnership with Lowe’s had enabled EcoBlu to implement new strategies
and boost contractor sales.

EcoBlu have established Nationwide Sales and Marketing of coatings
chemistry in South America, Caribbean, Africa and Asia.

A Three year plan of ECOB calls for direct selling of chemicals
coatings to mills, EWP manufacturers and independent coaters in the US
and elsewhere, than just selling to retailers and other small
builders.

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Dear Friends:

SNBP is our New Pick www.sinobiopharma.com

SINO BIOPHARMA SNBP a Fully integrated specality biopharmaceutical
company with 30,000 sq.meter Certified Production Facilities in China.

Estimated Chinese Health Care Market Demand of $600 Billion by 2015.We
all are aware China’s Current population is 1.4 Billion.

SNBP traded as high as $2.0 in the PAST, we can shoot for a gain of
8400%

Leadership of CEO Dr. Lequn Lee Huang a former manager of the Bayer
Co., one of the world's largest pharmaceutical companies and CFO Mr.
Dong Ying formerly of JP Morgan Chase.

SNBP Anesthetics Projected sale of 1.5 million units and 500,000
tablets for cardiovascular diseases in 2009.

Key Drives:
Outstanding financial results; more than 2000% growth in 3 years.
4 key marketed products; multiple products in pipeline.
R&D Partnership with Cornell University and 3 Top Universities in
China.
Established Nation wide Sales and Marketing Network in China.
Aging Population & Increasing Life Style diseases.
Improving Health Insurance Programs and Coverage.

PLAN FOR FUTURE: Sinobiopharma has a clearly defined strategy to drive
short, middle and long term growth.  All drug development will
leverage the Company's patented technology for fast, low-cost drug
synthesis and new technology for formulation.

Check out Complete Presentation only at www.stockexploder.com
Please do your own due diligence on SNBP
All The Best

Exploder

www.stockexploder.com
 *Never invest in a stock mentioned by stockexploder.com unless you
can afford to lose your entire investment. For full disclaimer
http://www.stockexploder.com/disclaimer.html

motley fool was saying the same thing when it was $5.75,$ 4.75 and
again now. The same with ALVR.

On Nov 14, 1:51 am, Zak <zak...@hotmail.com> wrote:

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

I am confident this is one of those long term plays that you let sit
in your portfolio and don't look at it for a year. When you come back
in a year, this stock will be a pleasant surprise.

Bottom line is: At $4.09 per share, this stock is tremendously
undervalued and oversold, not to mention solid financials to back it
up. As Motley Fool.com says: this stock is "poised to pop"!

Good luck Steve!

Zak

On Nov 13, 1:59 pm, Steve S <steve.syming...@gmail.com> wrote:

I'm right there with you, Zak; I more than doubled my position in AOB
today.

On Nov 13, 10:24 am, Zak <zak...@hotmail.com> wrote:

been following AOB for a year now.... i feel this is the time. china
is the future. i'm in for at least 4-5 years.

Zak

I believe they're set to release earnings next Monday (November 16,
2009).

See link here: http://money.cnn.com/news/newsfeeds/articles/prnewswire/200911091601P...

On Nov 9, 4:57 am, Matt <mat...@gmail.com> wrote:

It has been rumored that AOB is scheduled to report its 3Q 2009
financial results today, Monday, Nov. 9, but I have not seen any press
releases or announcements on the company's website, on the public
relations newswires, or in the other typical places you might expect,
such as Yahoo! Finance, Google Finance, etc. Is this happening today
or not? Before market open? After close? American Oriental
Bioengineering creates a lot of value for its shareholders, but I
think that the company would greatly benefit by communicating more
frequently with its American investors (such as myself), including
updating the website in a timely manner.

lets see it continue to ride upward.
visit www.roundupthebulls.com for market updates and big market
movers. they have been making great calls

There is really no good reason for this stock to be so oversold. I
think this is a rare opportunity to buy a company with these
fundamentals at as low as $4.20 per share. The fundamentals are
strong. They remain strong. What instigated this downturn since
September has been the publication of a research report by infamous
short-seller Manual Asensio, trying to raise questions about CEO Tony
Liu's undisclosed ties to other foreign companies. AOB has addressed
this issue on their website http://www.bioaobo.com and sought a cease
and desist order against Asensio. Asensio is not exactly an upstanding
character. Look him up. So I think the growth prospects for this
budding Chinese pharmaceutical/nutriceutical remain very strong, and I
think this is the last downturn we're going to see as the result of
reports issued by Asensio. This chart is extremely oversold by any
reasonable medium-to-long term measure, and you should buy before you
miss the bottom.

The shorts are having a f*cking FIELD DAY with this stock!! What the
heck? $4.23 at the moment.

AOB is going to be just fine.  It will be trading above $5.00 probably
as soon as next week.  Better get in while you still can.  I have been
watching the stock for a year now.  Its ridiculous with the market
upswing, proven earnings ability, and its growth potential, that it's
at this price...ridiculous.  Trust me.

On Oct 23, 2:31 pm, belt01 <matthewob...@gmail.com> wrote: